ACTU (43) TXMD (48) BYSI (42) KPTI (47) ⌘ Pro Terminal →

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) — RQD Stock Rating Cockpit

$2.44 +2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $20.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNTM)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

35.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $2$2.44H: $12

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on QNTM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like QNTM

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNTM)

✓Walkthrough of QNTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QNTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.42%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.45H $2.47L $2.29C $2.44VOL 76.8K

RES: $4.31SUP: $2.00SMA50: $3.12SMA200: $3.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNTM Butterfly Map → + Track QNTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QNTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QNTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNTM)

Health Care Rank #240 of 1016 ⚔️ ACTU vs QNTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNTM vs. ACTU, TXMD, BYSI, KPTI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) ranks #240 by composite RQD confidence (58/100, grade D+) and #831 by equity capitalization ($20.7M). Within this direct 5-issuer industry benchmark cohort, QNTM leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QNTM ACTIVE Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	Benchmark Subject
ACTU Actuate Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-qntm →
TXMD TherapeuticsMD Inc.	D	48/100	—	—	-12.9%	+2.24%	$21.2M	/txmd-vs-qntm →
BYSI BeyondSpring Inc.	D-	42/100	—	—	-35.0%	-1.49%	$21.2M	/bysi-vs-qntm →
KPTI Karyopharm Therapeutics Inc.	D	47/100	—	—	-35.0%	+5.73%	$20.0M	/kpti-vs-qntm →

2. QNTM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $20.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. QNTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $2.44 (+2.95% 1D, market cap $20.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, QNTM ranks #240 in composite RQD confidence.

How does QNTM compare to ACTU and TXMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $20.4M) and TXMD (TherapeuticsMD Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -12.9%, cap $21.2M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QNTM?

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #240 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QNTM trading relative to its 50-day, 200-day, and 52-week technical levels?

QNTM last traded at $2.44 (+2.95% on volume of 52,685 shares), positioning the stock -21.79% below its 50-day simple moving average ($3.12) and -37.11% below its 200-day simple moving average ($3.88). Across its 52-week range of $2.07 to $12.42, QNTM sits at the 3.6% percentile with a 14-day RSI of 35.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.14 to $2.74).

QNTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell QNTM stock right now?

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) currently earns a Roarable Rating of D+ (Sell — SELL) with 58/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is QNTM's 12-month price target and RQD AI Jury consensus?

QNTM's 12-month base price target is $2.44 (range $1.9 to $13.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: QNTM RQD Cockpit QNTM 12M Forecast QNTM Earnings & Move QNTM Dividends & DRIP QNTM Insiders & 13F QNTM Whale Options QNTM Profit Sankey QNTM News & Why